What NeuroPace (NPCE) Said on Its Q3 Earnings Call

Impact · against what's priced in

NPCE is facing a short-term setback due to a ~9% cut in 2026 revenue guidance driven by operational disruptions at major accounts and sales restructuring. While expense reductions and margin improvements provide some offset, the stock's immediate catalyst is negative, tempered slightly by 2027 growth targets and the IGE indication pipeline.

NPCE−0.40

No priced-in read yet

In context

The company reduced its 2026 revenue guidance to $91M–$92M from $99.5M–$101.5M following Q3 sales misses and internal disruptions. This top-line hit is partially mitigated by a raised gross margin forecast (83%–83.5%) and lowered operating expenses ($85M–$86M).

Read from the article alone

• revenue cutNew
• guidance
• earnings
• healthcare
• NPCE
• epilepsy
• fda
• medical devices
• sales force